Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-21

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to evaluate the safety and tolerability of HRS-3802 monotherapy in patients with advanced solid tumors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors

NCT06727812

Solid Tumors

RECRUITING PHASE1

Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

NCT05851092

Advanced Malignant Tumor

RECRUITING PHASE1

A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors

NCT06598735

Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1

A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.

NCT07032077

Solid Tumors

RECRUITING PHASE2

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

NCT06383871

Advanced Malignant Tumour

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HRS-3802

Group Type EXPERIMENTAL

HRS-3802

Intervention Type DRUG

HRS-3802

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HRS-3802

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits;
2. Age ≥18 years, male or female;
3. Patients with advanced malignant tumors confirmed pathologically;
4. Failure of adequate standard treatment, or no effective standard treatment;
5. Patients must have at least 1 extracranial measurable target lesion per RECIST v1.1;
6. The expected survival period is more than 12 weeks;
7. The Eastern Cooperative Oncology Group (ECOG) physical fitness score is 0 - 1;
8. Have sufficient bone marrow and organ function (have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days);
9. Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before starting the study medication, and the result is negative, and are willing to use a medically approved high-efficiency contraception during the study period and within 1 months after the last administration of the study drug Measures.

Exclusion Criteria

1. Subjects had cancerous meningitis or untreated central nervous system metastases;
2. Subjects had severe cardiovascular and cerebrovascular diseases;
3. There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion);
4. Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia;
5. Arteriovenous thrombosis occurred within 6 months prior to the first dose;
6. Severe infection occurred within 4 weeks prior to initial administration;
7. Subjects with refractory nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications: including malabsorption syndrome;
8. Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS);
9. Subjects had active hepatitis;
10. Subjects were scheduled to receive other systemic antitumor therapies during the study period;
11. Known allergies and contraindications to the investigational drug or any of its components;
12. Other factors as judged by the investigator that may lead to the termination of the study, such as other serious diseases, serious laboratory test abnormalities, or family or social factors that could affect the safety of the subject, or the collection of study data and samples.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.